PPARγ2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells
- 29 December 2008
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 106 (2), 232-246
- https://doi.org/10.1002/jcb.21994
Abstract
Rosiglitazone (Rosi), a member of the thiazolidinedione class of drugs used to treat type 2 diabetes, activates the adipocyte‐specific transcription factor peroxisome proliferator‐activated receptor gamma (PPARγ). This activation causes bone loss in animals and humans, at least in part due to suppression of osteoblast differentiation from marrow mesenchymal stem cells (MSC). In order to identify mechanisms by which PPARγ2 suppresses osteoblastogenesis and promotes adipogenesis in MSC, we have analyzed the PPARγ2 transcriptome in response to Rosi. A total of 4,252 transcriptional changes resulted when Rosi (1 µM) was applied to the U‐33 marrow stromal cell line stably transfected with PPARγ2 (U‐33/γ2) as compared to non‐induced U‐33/γ2 cells. Differences between U‐33/γ2 and U‐33 cells stably transfected with empty vector (U‐33/c) comprised 7,928 transcriptional changes, independent of Rosi. Cell type‐, time‐ and treatment‐specific gene clustering uncovered distinct patterns of PPARγ2 transcriptional control of MSC lineage commitment. The earliest changes accompanying Rosi activation of PPARγ2 included effects on Wnt, TGFβ/BMP and G‐protein signaling activities, as well as sustained induction of adipocyte‐specific gene expression and lipid metabolism. While suppression of osteoblast phenotype is initiated by a diminished expression of osteoblast‐specific signaling pathways, induction of the adipocyte phenotype is initiated by adipocyte‐specific transcriptional regulators. This indicates that distinct mechanisms govern the repression of osteogenesis and the stimulation of adipogenesis. The co‐expression patterns found here indicate that PPARγ2 has a dominant role in controlling osteoblast differentiation and suggests numerous gene‐gene interactions that could lead to the identification of a “master” regulatory scheme directing this process. J. Cell. Biochem. 106: 232–246, 2009.Keywords
This publication has 62 references indexed in Scilit:
- Runx2 Regulates G Protein-coupled Signaling Pathways to Control Growth of Osteoblast ProgenitorsOnline Journal of Public Health Informatics, 2008
- Functions of RANKL/RANK/OPG in bone modeling and remodelingArchives of Biochemistry and Biophysics, 2008
- Cytokine Signaling Modules in Inflammatory ResponsesImmunity, 2008
- Osteoblast expression of an engineered G s -coupled receptor dramatically increases bone massProceedings of the National Academy of Sciences of the United States of America, 2008
- PPARs and molecular mechanisms of transrepressionBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Estimatingp-values in small microarray experimentsBioinformatics, 2006
- Playing with bone and fatJournal of Cellular Biochemistry, 2006
- Improved statistical tests for differential gene expression by shrinking variance components estimatesBiostatistics, 2004
- A Direct Approach to False Discovery RatesJournal of the Royal Statistical Society Series B: Statistical Methodology, 2002
- Analysis of Variance for Gene Expression Microarray DataJournal of Computational Biology, 2000